{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T09:36:42Z","timestamp":1793957802177,"version":"4.8.0"},"reference-count":106,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1053\/j.seminoncol.2021.09.004","type":"journal-article","created":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T18:12:27Z","timestamp":1632334347000},"page":"193-207","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":112,"title":["Chemotherapy-induced peripheral neuropathy and rehabilitation: A review"],"prefix":"10.1053","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0112-717X","authenticated-orcid":false,"given":"Shangming","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1053\/j.seminoncol.2021.09.004_bib0001","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.pain.2014.09.020","article-title":"Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis","volume":"155","author":"Seretny","year":"2014","journal-title":"Pain"},{"issue":"7","key":"10.1053\/j.seminoncol.2021.09.004_bib0002","first-page":"2059","article-title":"Falls and functional impairments in cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study","volume":"21","author":"Gewandter","year":"2013","journal-title":"Support Care Cancer"},{"issue":"2","key":"10.1053\/j.seminoncol.2021.09.004_bib0003","first-page":"e12976","article-title":"Incidence, severity, longitudinal trends and predictors of acute and chronic oxaliplatin-induced peripheral neuropathy in Taiwanese patients with colorectal cancer","volume":"28","author":"Hsu","year":"2019","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"7","key":"10.1053\/j.seminoncol.2021.09.004_bib0004","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1097\/IGC.0000000000001320","article-title":"The influence of chemotherapy-induced peripheral neuropathy on quality of life of gynecologic cancer survivors","volume":"28","author":"Matsuoka","year":"2018","journal-title":"Int J Gynecol Cancer"},{"issue":"8","key":"10.1053\/j.seminoncol.2021.09.004_bib0005","first-page":"2261","article-title":"Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review","volume":"22","author":"Mols","year":"2014","journal-title":"Support Care Cancer"},{"issue":"21","key":"10.1053\/j.seminoncol.2021.09.004_bib0006","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1200\/JCO.2013.49.1514","article-title":"Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry","volume":"31","author":"Mols","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1053\/j.seminoncol.2021.09.004_bib0007","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ygyno.2015.11.011","article-title":"Chemotherapy-induced peripheral neuropathy: current status and progress","volume":"140","author":"Brewer","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1053\/j.seminoncol.2021.09.004_bib0008","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.pmr.2018.06.006","article-title":"Minimizing risk of cancer therapeutics","volume":"29","author":"Clark","year":"2018","journal-title":"Phys Med Rehabil Clin N Am"},{"key":"10.1053\/j.seminoncol.2021.09.004_bib0009","doi-asserted-by":"crossref","first-page":"e553","DOI":"10.14694\/EdBook_AM.2015.35.e553","article-title":"Chemotherapy-induced peripheral neurotoxicity in cancer survivors: an underdiagnosed clinical entity?","author":"Cavaletti","year":"2015","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"7","key":"10.1053\/j.seminoncol.2021.09.004_bib0010","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.clinph.2017.04.009","article-title":"Neurophysiological and clinical outcomes in chemotherapy-induced neuropathy in cancer","volume":"128","author":"Kandula","year":"2017","journal-title":"Clin Neurophysiol"},{"issue":"4","key":"10.1053\/j.seminoncol.2021.09.004_bib0011","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2217\/pmt.15.19","article-title":"Mechanisms involved in the development of chemotherapy-induced neuropathy","volume":"5","author":"Boyette-Davis","year":"2015","journal-title":"Pain Manag"},{"issue":"6","key":"10.1053\/j.seminoncol.2021.09.004_bib0012","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20061451","article-title":"Mechanisms of Chemotherapy-Induced Peripheral Neuropathy","volume":"20","author":"Zaj\u0105czkowska","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1053\/j.seminoncol.2021.09.004_bib0013","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1634\/theoncologist.2010-0248","article-title":"Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility","volume":"16","author":"Park","year":"2011","journal-title":"Oncologist"},{"issue":"6","key":"10.1053\/j.seminoncol.2021.09.004_bib0014","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11910-017-0757-7","article-title":"Update on Chemotherapy-induced peripheral neuropathy","volume":"17","author":"Cioroiu","year":"2017","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"6","key":"10.1053\/j.seminoncol.2021.09.004_bib0015","first-page":"419","article-title":"Chemotherapy-induced peripheral neurotoxicity: a critical analysis","volume":"63","author":"Park","year":"2013","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1053\/j.seminoncol.2021.09.004_bib0016","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1179\/joc.2004.16.Supplement-1.77","article-title":"Platinums: extending their therapeutic spectrum","volume":"16","author":"Muggia","year":"2004","journal-title":"J Chemother"},{"issue":"5","key":"10.1053\/j.seminoncol.2021.09.004_bib0017","doi-asserted-by":"crossref","first-page":"v3","DOI":"10.1093\/annonc\/mdm172","article-title":"Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents","volume":"18","author":"Fojo","year":"2007","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1053\/j.seminoncol.2021.09.004_bib0018","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00280-016-2976-z","article-title":"Platinum-based drugs: past, present and future","volume":"77","author":"Dilruba","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1053\/j.seminoncol.2021.09.004_bib0019","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/s41375-018-0205-y","article-title":"A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity","volume":"33","author":"Liu","year":"2019","journal-title":"Leukemia"},{"issue":"7","key":"10.1053\/j.seminoncol.2021.09.004_bib0020","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1634\/theoncologist.2015-0104","article-title":"Phase II clinical trial of Ixabepilone in metastatic cervical carcinoma","volume":"20","author":"Burotto","year":"2015","journal-title":"Oncologist"},{"key":"10.1053\/j.seminoncol.2021.09.004_bib0021","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3389\/fnins.2017.00481","article-title":"A mechanistic understanding of axon degeneration in chemotherapy-induced peripheral neuropathy","volume":"11","author":"Fukuda","year":"2017","journal-title":"Front Neurosci"},{"key":"10.1053\/j.seminoncol.2021.09.004_bib0022","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.neulet.2014.10.014","article-title":"Chemotherapy-induced peripheral neuropathy: what do we know about mechanisms?","volume":"596","author":"Carozzi","year":"2015","journal-title":"Neurosci Lett"},{"issue":"4","key":"10.1053\/j.seminoncol.2021.09.004_bib0023","first-page":"249","article-title":"Management of oxaliplatin-induced peripheral neuropathy","volume":"1","author":"Saif","year":"2005","journal-title":"Ther Clin Risk Manag"},{"issue":"3","key":"10.1053\/j.seminoncol.2021.09.004_bib0024","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0141-8130(00)00159-8","article-title":"Cisplatin stops tubulin assembly into microtubules. A new insight into the mechanism of antitumor activity of platinum complexes","volume":"28","author":"Tulub","year":"2001","journal-title":"Int J Biol Macromol"},{"key":"10.1053\/j.seminoncol.2021.09.004_bib0025","first-page":"371","article-title":"Update on taxane development: new analogs and new formulations","volume":"6","author":"Yared","year":"2012","journal-title":"Drug Des Devel Ther"},{"issue":"7","key":"10.1053\/j.seminoncol.2021.09.004_bib0026","doi-asserted-by":"crossref","first-page":"940","DOI":"10.4161\/cc.7.7.5625","article-title":"Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: a possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition","volume":"7","author":"Poruchynsky","year":"2008","journal-title":"Cell Cycle"},{"key":"10.1053\/j.seminoncol.2021.09.004_bib0027","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2147\/CMAR.S81310","article-title":"Expanding role of lenalidomide in hematologic malignancies","volume":"7","author":"Ghosh","year":"2015","journal-title":"Cancer Manag Res"},{"issue":"4","key":"10.1053\/j.seminoncol.2021.09.004_bib0028","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/hon.2149","article-title":"Therapy-related peripheral neuropathy in multiple myeloma patients","volume":"33","author":"Morawska","year":"2015","journal-title":"Hematol Oncol"},{"issue":"7","key":"10.1053\/j.seminoncol.2021.09.004_bib0029","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1523\/JNEUROSCI.3127-04.2005","article-title":"Activation of nuclear factor-kappaB via endogenous tumor necrosis factor alpha regulates survival of axotomized adult sensory neurons","volume":"25","author":"Fernyhough","year":"2005","journal-title":"J Neurosci"},{"issue":"24","key":"10.1053\/j.seminoncol.2021.09.004_bib0030","doi-asserted-by":"crossref","first-page":"7480","DOI":"10.1158\/1078-0432.CCR-06-2883","article-title":"Evidence for microtubule target engagement in tumors of patients receiving ixabepilone","volume":"13","author":"Zhuang","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1053\/j.seminoncol.2021.09.004_bib0031","first-page":"2661","article-title":"Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials","volume":"20","author":"Vahdat","year":"2012","journal-title":"Support Care Cancer"},{"issue":"1","key":"10.1053\/j.seminoncol.2021.09.004_bib0032","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1055\/s-2008-1040868","article-title":"Neuropathies associated with malignancy","volume":"18","author":"Amato","year":"1998","journal-title":"Semin Neurol"},{"issue":"3","key":"10.1053\/j.seminoncol.2021.09.004_bib0033","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/mus.20163","article-title":"Lymphoma and peripheral neuropathy: a clinical review","volume":"31","author":"Kelly","year":"2005","journal-title":"Muscle Nerve"},{"issue":"5","key":"10.1053\/j.seminoncol.2021.09.004_bib0034","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3949\/ccjm.76a.08070","article-title":"Small fiber neuropathy: a burning problem","volume":"76","author":"Tavee","year":"2009","journal-title":"Cleve Clin J Med"},{"issue":"10","key":"10.1053\/j.seminoncol.2021.09.004_bib0035","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1002\/cncr.24981","article-title":"Long-term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancer","volume":"116","author":"Glendenning","year":"2010","journal-title":"Cancer"},{"issue":"22","key":"10.1053\/j.seminoncol.2021.09.004_bib0036","doi-asserted-by":"crossref","first-page":"5082","DOI":"10.1158\/1078-0432.CCR-15-0586","article-title":"Genome-wide association studies for taxane-induced peripheral neuropathy in ECOG-5103 and ECOG-1199","volume":"21","author":"Schneider","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1053\/j.seminoncol.2021.09.004_bib0037","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/j.seminoncol.2005.12.010","article-title":"Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy","volume":"33","author":"Hausheer","year":"2006","journal-title":"Semin Oncol"},{"issue":"3","key":"10.1053\/j.seminoncol.2021.09.004_bib0038","first-page":"223","article-title":"Is advanced age associated with increased incidence and severity of chemotherapy-induced peripheral neuropathy?","volume":"14","author":"Argyriou","year":"2006","journal-title":"Support Care Cancer"},{"issue":"1","key":"10.1053\/j.seminoncol.2021.09.004_bib0039","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1600-0609.2010.01533.x","article-title":"Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study","volume":"86","author":"Dimopoulos","year":"2011","journal-title":"Eur J Haematol"},{"issue":"6","key":"10.1053\/j.seminoncol.2021.09.004_bib0040","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1212\/01.wnl.0000267271.18475.fe","article-title":"Neuropathy in multiple myeloma treated with thalidomide: a prospective study","volume":"69","author":"Plasmati","year":"2007","journal-title":"Neurology"},{"issue":"4","key":"10.1053\/j.seminoncol.2021.09.004_bib0041","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3727\/096504012X13522227232192","article-title":"Factors exacerbating peripheral neuropathy induced by paclitaxel plus carboplatin in non-small cell lung cancer","volume":"20","author":"Kawakami","year":"2012","journal-title":"Oncol Res"},{"issue":"1","key":"10.1053\/j.seminoncol.2021.09.004_bib0042","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2146\/ajhp130126","article-title":"Prevention and treatment of chemotherapy-induced peripheral neuropathy","volume":"71","author":"Piccolo","year":"2014","journal-title":"Am J Health Syst Pharm"},{"issue":"28","key":"10.1053\/j.seminoncol.2021.09.004_bib0043","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1200\/JCO.20.01399","article-title":"Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update","volume":"38","author":"Loprinzi","year":"2020","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1053\/j.seminoncol.2021.09.004_bib0044","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1634\/theoncologist.2017-0235","article-title":"Pregabalin for the prevention of oxaliplatin-induced painful neuropathy: a randomized, double-blind trial","volume":"22","author":"de Andrade","year":"2017","journal-title":"Oncologist"},{"issue":"7","key":"10.1053\/j.seminoncol.2021.09.004_bib0045","first-page":"2601","article-title":"Amitriptyline in the prevention of chemotherapy-induced neuropathic symptoms","volume":"29","author":"Kautio","year":"2009","journal-title":"Anticancer Res"},{"issue":"12","key":"10.1053\/j.seminoncol.2021.09.004_bib0046","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1016\/j.ejca.2005.04.028","article-title":"Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine","volume":"41","author":"Bianchi","year":"2005","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1053\/j.seminoncol.2021.09.004_bib0047","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1212\/WNL.0b013e31822e045c","article-title":"Retinoic acid reduces chemotherapy-induced neuropathy in an animal model and patients with lung cancer","volume":"77","author":"Arrieta","year":"2011","journal-title":"Neurology"},{"issue":"2","key":"10.1053\/j.seminoncol.2021.09.004_bib0048","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s002800050723","article-title":"Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin","volume":"41","author":"Cassidy","year":"1998","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1053\/j.seminoncol.2021.09.004_bib0049","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/annonc\/mdr045","article-title":"Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial","volume":"23","author":"Durand","year":"2012","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1053\/j.seminoncol.2021.09.004_bib0050","article-title":"Interventions for preventing neuropathy caused by cisplatin and related compounds","author":"Albers","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1053\/j.seminoncol.2021.09.004_bib0051","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1200\/JCO.1995.13.1.26","article-title":"Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial","volume":"13","author":"Cascinu","year":"1995","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1053\/j.seminoncol.2021.09.004_bib0052","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1200\/JCO.2002.07.061","article-title":"Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial","volume":"20","author":"Cascinu","year":"2002","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1053\/j.seminoncol.2021.09.004_bib0053","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1200\/JCO.1996.14.7.2101","article-title":"Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer","volume":"14","author":"Kemp","year":"1996","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1053\/j.seminoncol.2021.09.004_bib0054","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1093\/annonc\/mdg301","article-title":"Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients","volume":"14","author":"Lorusso","year":"2003","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1053\/j.seminoncol.2021.09.004_bib0055","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1212\/01.wnl.0000249344.99671.d4","article-title":"Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy","volume":"67","author":"Argyriou","year":"2006","journal-title":"Neurology"},{"issue":"3","key":"10.1053\/j.seminoncol.2021.09.004_bib0056","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1634\/theoncologist.12-3-312","article-title":"Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients","volume":"12","author":"Wang","year":"2007","journal-title":"Oncologist"},{"issue":"12","key":"10.1053\/j.seminoncol.2021.09.004_bib0057","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1002\/cncr.28654","article-title":"North Central Cancer Treatment Group\/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel\/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study","volume":"120","author":"Leal","year":"2014","journal-title":"Cancer"},{"issue":"1","key":"10.1053\/j.seminoncol.2021.09.004_bib0058","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ygyno.2004.11.052","article-title":"A randomized phase II study of paclitaxel with carboplatin +\/- amifostine as first line treatment in advanced ovarian carcinoma","volume":"97","author":"De Vos","year":"2005","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1053\/j.seminoncol.2021.09.004_bib0059","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1158\/1078-0432.CCR-0772-03","article-title":"Neurophysiological study of peripheral neuropathy after high-dose Paclitaxel: lack of neuroprotective effect of amifostine","volume":"10","author":"Openshaw","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1053\/j.seminoncol.2021.09.004_bib0060","first-page":"78","article-title":"Long-term glutamate supplementation failed to protect against peripheral neurotoxicity of paclitaxel","volume":"18","author":"Loven","year":"2009","journal-title":"Eur J Cancer Care (Engl)"},{"key":"10.1053\/j.seminoncol.2021.09.004_bib0061","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3389\/fphar.2019.00365","article-title":"Duloxetine, a balanced serotonin-norepinephrine reuptake inhibitor, improves painful chemotherapy-induced peripheral neuropathy by inhibiting activation of p38 MAPK and NF-\u03baB","volume":"10","author":"Meng","year":"2019","journal-title":"Front Pharmacol"},{"issue":"4","key":"10.1053\/j.seminoncol.2021.09.004_bib0062","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1080\/0284186X.2018.1556804","article-title":"Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy","volume":"58","author":"Soveri","year":"2019","journal-title":"Acta Oncol"},{"issue":"3","key":"10.1053\/j.seminoncol.2021.09.004_bib0063","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/cam4.1976","article-title":"Daily activity, mood, and quality of life in colorectal cancer patients with chemotherapy-induced peripheral neuropathy: a mediation effect analysis","volume":"8","author":"Lu","year":"2019","journal-title":"Cancer Med"},{"issue":"3","key":"10.1053\/j.seminoncol.2021.09.004_bib0064","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/s11764-015-0427-1","article-title":"Chemotherapy-induced peripheral neuropathy, physical activity and health-related quality of life among colorectal cancer survivors from the PROFILES registry","volume":"9","author":"Mols","year":"2015","journal-title":"J Cancer Surviv"},{"issue":"3","key":"10.1053\/j.seminoncol.2021.09.004_bib0065","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.ygyno.2018.03.052","article-title":"Course of chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer patients: A longitudinal study","volume":"149","author":"Bonhof","year":"2018","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1053\/j.seminoncol.2021.09.004_bib0066","first-page":"2411","article-title":"Chemotherapy-induced neuropathy in multiple myeloma: influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice","volume":"24","author":"Beijers","year":"2016","journal-title":"Support Care Cancer"},{"issue":"23","key":"10.1053\/j.seminoncol.2021.09.004_bib0067","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1200\/JCO.2016.71.3552","article-title":"Falls, functioning, and disability among women with persistent symptoms of chemotherapy-induced peripheral neuropathy","volume":"35","author":"Winters-Stone","year":"2017","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1053\/j.seminoncol.2021.09.004_bib0068","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1212\/01.WNL.0000092015.03923.19","article-title":"Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale","volume":"61","author":"Cavaletti","year":"2003","journal-title":"Neurology"},{"issue":"2","key":"10.1053\/j.seminoncol.2021.09.004_bib0069","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1093\/annonc\/mds329","article-title":"The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings","volume":"24","author":"Cavaletti","year":"2013","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1053\/j.seminoncol.2021.09.004_bib0070","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"10.1053\/j.seminoncol.2021.09.004_bib0071","first-page":"741","article-title":"Psychometric evaluation of the Functional Assessment of Cancer Therapy\/Gynecologic Oncology Group-Neurotoxicity (Fact\/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy","volume":"13","author":"Calhoun","year":"2003","journal-title":"Int J Gynecol Cancer"},{"issue":"12","key":"10.1053\/j.seminoncol.2021.09.004_bib0072","first-page":"1483","article-title":"Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02","volume":"17","author":"Shimozuma","year":"2009","journal-title":"Support Care Cancer"},{"issue":"4","key":"10.1053\/j.seminoncol.2021.09.004_bib0073","first-page":"877","article-title":"Assessing the impact of chemotherapy-induced peripheral neurotoxicity on the quality of life of cancer patients: the introduction of a new measure","volume":"20","author":"Driessen","year":"2012","journal-title":"Support Care Cancer"},{"issue":"9","key":"10.1053\/j.seminoncol.2021.09.004_bib0074","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1002\/cncr.23008","article-title":"Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3)","volume":"110","author":"Rao","year":"2007","journal-title":"Cancer"},{"issue":"1-2","key":"10.1053\/j.seminoncol.2021.09.004_bib0075","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0304-3959(02)00047-7","article-title":"Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy","volume":"98","author":"Hammack","year":"2002","journal-title":"Pain"},{"issue":"1","key":"10.1053\/j.seminoncol.2021.09.004_bib0076","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jpainsymman.2007.02.043","article-title":"Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms","volume":"35","author":"Kautio","year":"2008","journal-title":"J Pain Symptom Manage"},{"issue":"12","key":"10.1053\/j.seminoncol.2021.09.004_bib0077","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1002\/cncr.23482","article-title":"Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled trial, N01C3","volume":"112","author":"Rao","year":"2008","journal-title":"Cancer"},{"issue":"6","key":"10.1053\/j.seminoncol.2021.09.004_bib0078","first-page":"833","article-title":"A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA","volume":"19","author":"Barton","year":"2011","journal-title":"Support Care Cancer"},{"issue":"13","key":"10.1053\/j.seminoncol.2021.09.004_bib0079","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jama.2013.2813","article-title":"Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial","volume":"309","author":"Smith","year":"2013","journal-title":"JAMA"},{"issue":"5","key":"10.1053\/j.seminoncol.2021.09.004_bib0080","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1007\/s10147-015-0810-y","article-title":"Effect of duloxetine in Japanese patients with chemotherapy-induced peripheral neuropathy: a pilot randomized trial","volume":"20","author":"Hirayama","year":"2015","journal-title":"Int J Clin Oncol"},{"issue":"7","key":"10.1053\/j.seminoncol.2021.09.004_bib0081","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.jacc.2015.06.1084","article-title":"Orthostatic hypotension: epidemiology, prognosis, and treatment","volume":"66","author":"Ricci","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1053\/j.seminoncol.2021.09.004_bib0082","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1177\/1534735418807555","article-title":"Effects of aerobic and resistance exercises on physical symptoms in cancer patients: a meta-analysis","volume":"17","author":"Nakano","year":"2018","journal-title":"Integr Cancer Ther"},{"key":"10.1053\/j.seminoncol.2021.09.004_bib0083","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.critrevonc.2017.11.002","article-title":"Effects of exercise on cancer patients suffering chemotherapy-induced peripheral neuropathy undergoing treatment: a systematic review","volume":"121","author":"Duregon","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"10.1053\/j.seminoncol.2021.09.004_bib0084","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1053\/j.seminoncol.2013.09.008","article-title":"Physical functioning and rehabilitation for the cancer survivor","volume":"40","author":"Stubblefield","year":"2013","journal-title":"Semin Oncol"},{"issue":"2","key":"10.1053\/j.seminoncol.2021.09.004_bib0085","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/annonc\/mdt568","article-title":"Exercise program improves therapy-related side-effects and quality of life in lymphoma patients undergoing therapy","volume":"25","author":"Streckmann","year":"2014","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1053\/j.seminoncol.2021.09.004_bib0086","first-page":"2471","article-title":"Sensorimotor training and whole-body vibration training have the potential to reduce motor and sensory symptoms of chemotherapy-induced peripheral neuropathy-a randomized controlled pilot trial","volume":"27","author":"Streckmann","year":"2019","journal-title":"Support Care Cancer"},{"issue":"9","key":"10.1053\/j.seminoncol.2021.09.004_bib0087","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1007\/s00432-018-2686-5","article-title":"Evaluation of the effects of sensorimotor exercise on physical and psychological parameters in breast cancer patients undergoing neurotoxic chemotherapy","volume":"144","author":"Vollmers","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"issue":"23","key":"10.1053\/j.seminoncol.2021.09.004_bib0088","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1093\/jnci\/djt297","article-title":"Effects of exercise dose and type during breast cancer chemotherapy: multicenter randomized trial","volume":"105","author":"Courneya","year":"2013","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1053\/j.seminoncol.2021.09.004_bib0089","first-page":"95","article-title":"Strength and endurance training in the treatment of lung cancer patients in stages IIIA\/IIIB\/IV","volume":"22","author":"Henke","year":"2014","journal-title":"Support Care Cancer"},{"issue":"4","key":"10.1053\/j.seminoncol.2021.09.004_bib0090","first-page":"1019","article-title":"Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial","volume":"26","author":"Kleckner","year":"2018","journal-title":"Support Care Cancer"},{"issue":"2","key":"10.1053\/j.seminoncol.2021.09.004_bib0091","first-page":"615","article-title":"Eight-week, multimodal exercise counteracts a progress of chemotherapy-induced peripheral neuropathy and improves balance and strength in metastasized colorectal cancer patients: a randomized controlled trial","volume":"26","author":"Zimmer","year":"2018","journal-title":"Support Care Cancer"},{"key":"10.1053\/j.seminoncol.2021.09.004_bib0092","doi-asserted-by":"crossref","first-page":"b3410","DOI":"10.1136\/bmj.b3410","article-title":"Effect of a multimodal high intensity exercise intervention in cancer patients undergoing chemotherapy: randomised controlled trial","volume":"339","author":"Adamsen","year":"2009","journal-title":"BMJ"},{"issue":"4","key":"10.1053\/j.seminoncol.2021.09.004_bib0093","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/MRR.0000000000000196","article-title":"Effect of lower limb closed kinematic chain exercises on balance in patients with chemotherapy-induced peripheral neuropathy: a pilot study","volume":"39","author":"Fernandes","year":"2016","journal-title":"Int J Rehabil Res"},{"issue":"6","key":"10.1053\/j.seminoncol.2021.09.004_bib0094","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1097\/IGC.0000000000000460","article-title":"An exercise intervention during chemotherapy for women with recurrent ovarian cancer: a feasibility study","volume":"25","author":"Mizrahi","year":"2015","journal-title":"Int J Gynecol Cancer"},{"key":"10.1053\/j.seminoncol.2021.09.004_bib0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4172\/2329-9096.1000210","article-title":"The effect of supervised exercise training on symptoms of chemotherapy-induced peripheral neuropathy","volume":"2","author":"Wonders","year":"2014","journal-title":"Int J Phys Med Rehabil"},{"issue":"10","key":"10.1053\/j.seminoncol.2021.09.004_bib0096","first-page":"3849","article-title":"Exercise-based rehabilitation for cancer survivors with chemotherapy-induced peripheral neuropathy","volume":"27","author":"McCrary","year":"2019","journal-title":"Support Care Cancer"},{"issue":"3","key":"10.1053\/j.seminoncol.2021.09.004_bib0097","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1177\/2156587212450175","article-title":"Effects of reiki, yoga, or meditation on the physical and psychological symptoms of chemotherapy-induced peripheral neuropathy: a randomized pilot study","volume":"17","author":"Clark","year":"2012","journal-title":"J Evid-Based Complement Alter Med"},{"issue":"9","key":"10.1053\/j.seminoncol.2021.09.004_bib0098","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1038\/bjc.2014.466","article-title":"Subgroup effects in a randomised trial of different types and doses of exercise during breast cancer chemotherapy","volume":"111","author":"Courneya","year":"2014","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1053\/j.seminoncol.2021.09.004_bib0099","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/NCC.0000000000000693","article-title":"A randomized controlled trial to assess the effectiveness of muscle strengthening and balancing exercises on chemotherapy-induced peripheral neuropathic pain and quality of life among cancer patients","volume":"43","author":"Dhawan","year":"2020","journal-title":"Cancer Nurs"},{"issue":"3","key":"10.1053\/j.seminoncol.2021.09.004_bib0100","doi-asserted-by":"crossref","first-page":"E172","DOI":"10.1097\/NCC.0000000000000801","article-title":"Exercise effects on chemotherapy-induced peripheral neuropathy: a comprehensive integrative review","volume":"43","author":"Kanzawa-Lee","year":"2020","journal-title":"Cancer Nurs"},{"issue":"17","key":"10.1053\/j.seminoncol.2021.09.004_bib0101","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1200\/JCO.2014.59.1081","article-title":"Effect of low-intensity physical activity and moderate- to high-intensity physical exercise during adjuvant chemotherapy on physical fitness, fatigue, and chemotherapy completion rates: results of the PACES randomized clinical trial","volume":"33","author":"van Waart","year":"2015","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1053\/j.seminoncol.2021.09.004_bib0102","first-page":"295","article-title":"Impairment-driven cancer rehabilitation: an essential component of quality care and survivorship","volume":"63","author":"Silver","year":"2013","journal-title":"CA Cancer J Clin"},{"issue":"9 Suppl 2","key":"10.1053\/j.seminoncol.2021.09.004_bib0103","first-page":"S291","article-title":"Integrating rehabilitation into the cancer care continuum","volume":"9","author":"Silver","year":"2017","journal-title":"PM R"},{"issue":"9S2","key":"10.1053\/j.seminoncol.2021.09.004_bib0104","first-page":"S305","article-title":"The case for prehabilitation prior to breast cancer treatment","volume":"9","author":"Santa","year":"2017","journal-title":"PM R"},{"issue":"9S2","key":"10.1053\/j.seminoncol.2021.09.004_bib0105","doi-asserted-by":"crossref","first-page":"S324","DOI":"10.1016\/j.pmrj.2017.04.017","article-title":"A guide to inpatient cancer rehabilitation: focusing on patient selection and evidence-based outcomes","volume":"9","author":"Fu","year":"2017","journal-title":"PM R"},{"issue":"9S2","key":"10.1053\/j.seminoncol.2021.09.004_bib0106","doi-asserted-by":"crossref","first-page":"S317","DOI":"10.1016\/j.pmrj.2017.05.010","article-title":"The underutilization of rehabilitation to treat physical impairments in breast cancer survivors","volume":"9","author":"Stubblefield","year":"2017","journal-title":"PM R"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775421000567?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775421000567?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T12:55:58Z","timestamp":1758804958000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775421000567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":106,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S0093775421000567"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2021.09.004","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemotherapy-induced peripheral neuropathy and rehabilitation: A review","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminoncol.2021.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}